According to the National Academy of Clinical Biochemistry Guidelines for the use of Tumor Markers in Lung Cancer, recommended markers are Cyfra21‐1 and CEA before therapy and Cyfra21‐1 and/or CEA in post‐therapy follow‐up in patients with adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The gene discussed is CEACAM5; the disease is neoplasm.